Clinical trials applying BTZ solo or combined with other anti-cancer agents in phases I, II, and III on non-Hodgkin lymphoma, myeloid leukemia, and multiple myeloma patients have demonstrated promising responses, considering response rate, time to progression, and survival.26-28 Several investigations have shown the potential of BTZ for treating fibrosis, such as kidney fibrosis.29,30 BTZ’s potential antifibrotic actions have attracted interest in fatty liver and fibrosis correlated with inflammation. This evidence concerns the gene CASC3 and plasma cell myeloma.